Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
Neven
P
P
Multidisciplinary Breast Center; Department of Obstetrics and Gynecology, UZ-Leuven, Catholic University Leuven, Leuven, Belgium.
Paridaens
R
R
Amant
F
F
Wildiers
H
H
Berteloot
P
P
Leunen
K
K
Smeets
A
A
Weltens
C
C
van den Bogaert
W
W
van Limbergen
E
E
Christiaens
M R
MR
Vergote
I
I
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000378:metabolism*; D013629:Tamoxifen / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D013629:Tamoxifen